Evidence map›Paper›PMID 41036492›Full record

ArticleGynecologic oncology reports2025

Treatment preferences of patients with recurrent or metastatic cervical cancer: a discrete choice experiment in the US.

Premal H Thaker, Hui Lu, Yitong J Zhang, Myrto Trapali, Paul Swinburn, Nicolas Krucien, Doris White, Joslyn Chaiprasert-Paguio, Bhavana Pothuri, Jie Ting

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Premal H ThakerWashington University School of Medicine and Siteman Cancer Center, St. Louis, MO, USA.
Hui LuEvidera, London, UK.
Yitong J ZhangPfizer Inc, Bothell, WA, USA.
Myrto TrapaliEvidera, London, UK.
Paul SwinburnEvidera, London, UK.
Nicolas KrucienEvidera, London, UK.
Doris WhiteCervivor, Inc., Upper Marlboro, MD, USA.
Joslyn Chaiprasert-PaguioCervivor, Inc., Upper Marlboro, MD, USA.
Bhavana PothuriPerlmutter Cancer Center, NYU Langone Health, NYU Grossman School of Medicine, New York, NY, USA.
Jie TingPfizer Inc, Bothell, WA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study assessed treatment preferences of patients with recurrent/metastatic cervical cancer, a disease with poor prognosis. Methods: A survey with two discrete choice experiments was completed by 150 patients with recurrent/metastatic cervical cancer in the US. Discrete choice experiment 1 included treatment attributes, and discrete choice experiment 2 included risk mitigation plan attributes. Results: Participants valued 12-month overall survival rate as the most important attribute, followed by disease control rate; both efficacy attributes were rated as more important than the risk of side effects such as peripheral neuropathy and corneal side effects. Participants' willingness to accept a treatment profile requiring a risk mitigation plan was influenced by the number of clinic visits and out-of-pocket costs. Conclusions: Patients with recurrent/metastatic cervical cancer prioritize overall survival and disease control rate as the most important attributes. These findings can be used to inform shared decision-making and treatment discussions among patients, clinicians, and the care team.

Indexed as

Benefit-risk profileCervical cancerDiscrete choice experimentFinancial burdenOverall survivalPatient preferences

Identifiers

PMID41036492
PMCPMC12481111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.